Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,006 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The NICE cost-effectiveness threshold: what it is and what that means.
McCabe C, Claxton K, Culyer AJ. McCabe C, et al. Pharmacoeconomics. 2008;26(9):733-44. doi: 10.2165/00019053-200826090-00004. Pharmacoeconomics. 2008. PMID: 18767894 Review.
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.
Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K, Miller DH; Cost Effectiveness of Multiple Sclerosis Therapies Study Group. Chilcott J, et al. Among authors: mccabe c. BMJ. 2003 Mar 8;326(7388):522; discussion 522. doi: 10.1136/bmj.326.7388.522. BMJ. 2003. PMID: 12623909 Free PMC article.
Whither trial-based economic evaluation for health care decision making?
Sculpher MJ, Claxton K, Drummond M, McCabe C. Sculpher MJ, et al. Among authors: mccabe c. Health Econ. 2006 Jul;15(7):677-87. doi: 10.1002/hec.1093. Health Econ. 2006. PMID: 16491461
Should patients have a greater role in valuing health states?
Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, Sculpher M, Tsuchyia A. Brazier J, et al. Among authors: mccabe c. Appl Health Econ Health Policy. 2005;4(4):201-8. doi: 10.2165/00148365-200504040-00002. Appl Health Econ Health Policy. 2005. PMID: 16466271
Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion.
Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J. Claxton K, et al. Among authors: mccabe c. Health Econ. 2006 Jan;15(1):1-4. doi: 10.1002/hec.1081. Health Econ. 2006. PMID: 16365910
Cost effectiveness of HMG-CoA reductase inhibitors in the management of coronary artery disease: the problem of under-treatment.
McCabe C. McCabe C. Am J Cardiovasc Drugs. 2003;3(3):179-91. doi: 10.2165/00129784-200303030-00004. Am J Cardiovasc Drugs. 2003. PMID: 14727930 Review.
Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra.
Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J, O'Hagan T. Claxton K, et al. Among authors: mccabe c. Health Econ. 2005 Apr;14(4):339-47. doi: 10.1002/hec.985. Health Econ. 2005. PMID: 15736142
Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis. The impact on costs and outcomes in the UK.
McCabe CJ, Akehurst RL, Kirsch J, Whitfield M, Backhouse M, Woolf AD, Scott DL, Emery P, Haslock I. McCabe CJ, et al. Pharmacoeconomics. 1998 Aug;14(2):191-9. doi: 10.2165/00019053-199814020-00007. Pharmacoeconomics. 1998. PMID: 10186459
Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
Pickin DM, McCabe CJ, Ramsay LE, Payne N, Haq IU, Yeo WW, Jackson PR. Pickin DM, et al. Among authors: mccabe cj. Heart. 1999 Sep;82(3):325-32. doi: 10.1136/hrt.82.3.325. Heart. 1999. PMID: 10455083 Free PMC article.
Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?
Edlin R, Hall P, Wallner K, McCabe C. Edlin R, et al. Among authors: mccabe c. Value Health. 2014 Jun;17(4):438-44. doi: 10.1016/j.jval.2014.01.010. Epub 2014 Apr 29. Value Health. 2014. PMID: 24969005
1,006 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page